Anti-EphA2 antibodies with distinct in vitro properties have equal in vivo efficacy in pancreatic cancer

Journal of Oncology

Volumn , Issue , 2009, Pages

  Vitelli, Alessandra ^a   Ansuini, Helenia ^a   Meola, Annalisa ^a   Gunes, Zeynep ^a   Paradisi, Valentina ^b   Pezzanera, Monica ^a   Acali, Stefano ^a   Santini, Claudia ^a   Luzzago, Alessandra ^a   Mori, Federica ^a   Lazzaro, Domenico ^a   Ciliberto, Gennaro ^a   Nicosia, Alfredo ^c   La Monica, Nicola ^a  

^a IRBM   (Italy)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c Okairos ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A2 ANTIBODY; FOCAL ADHESION KINASE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IGG25; MONOCLONAL ANTIBODY IGG28; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INTERNALIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PANCREAS CANCER; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 76349093391     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2009/951917     Document Type: Article

References (27)

1. Lackmann M., Boyd A. W., Eph, a protein family coming of age: more confusion, insight, or complexity? Science Signaling 2008 13 1 16
2. Pasquale E. B., Eph receptor signaling casts a wide net on cell behavior Nature Reviews 2005 6 462 475
3. Pasquale E. B., Eph-ephrin bidirectional signaling in physiology and disease Cell 2008 133 1 38 52
4. Merlos-Surez A., Batlle E., Eph-ephrin signaling in adult tissues and cancer Current Opinion in Cell Biology 2008 20 194 200
5. Ireton R. C., Chen J., EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics Current Cancer Drug Targets 2005 5 3 149 157
6. Wykosky J., Debinski W., The EphA2 receptor and EphrinA1 ligand in solid tumors: function and therapeutic targeting Molecular Cancer Research 2008 6 12 1795 1806
7. Zantek N. D., Walker-Daniels J., Stewart J., MCF-10A-NeoST: a new cell system for studying cell-ECM and cell-cell interactions in breast cancer Clinical Cancer Research 2001 7 11 3640 3648
8. Walker-Daniels J., Riese D. J. II, Kinch M. S., c-Cbl-dependent EphA2 protein degradation is induced by ligand binding Molecular Cancer Research 2002 1 1 79 87
9. Guo H., Miao H., Gerber L., Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin Cancer Research 2006 66 14 7050 7058
10. Ogawa K., Pasqualini R., Lindberg R. A., The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization Oncogene 2000 19 52 6043 6052
11. Dobrzanski P., Hunter K., Jones-Bolin S., Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist Cancer Research 2004 64 3 910 919
12. Fang W. B., Brantley-Sieders D. M., Parker M. A., A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis Oncogene 2005 24 53 7859 7868
13. Kataoka H., Igarashi H., Kanamori M., Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer Cancer Science 2004 95 2 136 141
14. Carles-Kinch K., Kilpatrick K. E., Stewart J. C., Kinch M. S., Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior Cancer Research 2002 62 10 2840 2847
15. Duxbury M. S., Ito H., Zinner M. J., EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma Oncogene 2004 23 7 1448 1456
16. Clarke P., Mann J., Simpson J. F., Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy Cancer Research 1998 58 7 1469 1477
17. Catalucci D., Sporeno E., Cirillo A., An adenovirus type 5 (Ad5) amplicon-based packaging cell line for production of high-capacity helper-independent deltaE1-E2-E3-E4 Ad5 vectors The Journal of Virology 2005 79 10 6400 6409
18. Monaci P., Luzzago A., Santini C., Differential screening of phage-Ab libraries by oligonucleotide microarray technology PLoS ONE 2008 3 1 1 10
19. Brantley D. M., Cheng N., Thompson E. J., Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo Oncogene 2002 21 46 7011 7026
20. Cheng N., Brantley D., Fang W. B., Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors Neoplasia 2003 5 5 445 456
21. Kiewlich D., Zhang J., Gross C., Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth Neoplasia 2006 8 1 18 30
22. Kinch M. S., Carles-Kinch K., Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer Clinical and Experimental Metastasis 2003 20 1 59 68
23. Macrae M., Neve R. M., Rodriguez-Viciana P., A conditional feedback loop regulates Ras activity through EphA2 Cancer Cell 2005 8 2 111 118
24. Chang Q., Jorgensen C., Pawson T., Hedley D. W., Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer British Journal of Cancer 2008 99 7 1074 1082
25. Menges C. W., McCance D. J., Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor Oncogene 2007 27 20 2934 2940
26. Carter N., Nakamoto T., Hirai H., Hunter T., EphrinA1-induced cytoskeletal re-organization requires FAK and p130cas Nature Cell Biology 2002 4 8 565 573
27. Parri M., Buricchi F., Giannoni E., EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to Rho-dependent actino/myosin contractility The Journal of Biological Chemistry 2007 282 27 19619 19628